Ranbaxy's Singhs are $100M wealthier this year

The latest Forbes rich list showed the trials and travails of the globe's most wealthy: the number of billionaires on the planet dropped last year. But India's "pharmaceutical kings" Malvinder and Shivinder Singh--of Ranbaxy Laboratories fame--actually added $100 million to their combined net worth. Thank you, Daiichi Sankyo! Report

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

Pfizer terminated a slew of trial cohorts testing Bavencio in combination with its own experimental drugs, as well as one monotherapy trial.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.